• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Dacosta Albert bought $255,226 worth of shares (28,000 units at $9.12) (SEC Form 4)

    3/18/24 5:34:02 PM ET
    $FNA
    Medical/Dental Instruments
    Health Care
    Get the next $FNA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    DaCosta Albert

    (Last) (First) (Middle)
    C/O PARAGON 28, INC.
    14445 GRASSLANDS DRIVE

    (Street)
    ENGLEWOOD CO 80112

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Paragon 28, Inc. [ FNA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director X 10% Owner
    X Officer (give title below) Other (specify below)
    See Remarks
    3. Date of Earliest Transaction (Month/Day/Year)
    03/15/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 03/15/2024 P 28,000 A $9.1152(1) 5,339,110 I See footnote(2)
    Common Stock 5,000,000 I See footnote(3)
    Common Stock 25,000 I By Spouse
    Common Stock 643,336(4) D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The price reported in Column 4 is a weighted average price. The shares were puchased in mulitple transactions at prices ranging from $8.93 to $9.18, inclusive. Full information regarding the number of shares purchased at each separate price will be furnished to the SEC staff upon request.
    2. Shares are held by The DaCosta Family Trust, of which the Reporting Person is trustee.
    3. Shares are held by DaCosta Investment Company, LLC, of which the Reporting Person is a manager.
    4. Includes 398,388 restricted stock units.
    Remarks:
    President & Chief Executive Officer
    /s/ Robert McCormack, as Attorney-in-Fact for Albert DaCosta 03/18/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $FNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FNA

    DatePrice TargetRatingAnalyst
    1/29/2025Buy → Hold
    Needham
    1/29/2025Outperform → Mkt Perform
    William Blair
    9/29/2023Outperform
    William Blair
    4/11/2023$23.00Overweight
    Stephens
    12/14/2022$32.00Buy
    B. Riley Securities
    3/9/2022$30.00 → $25.00Buy
    B of A Securities
    3/9/2022$25.00 → $23.00Buy
    Canaccord Genuity
    2/9/2022$31.00 → $25.00Buy
    Needham
    More analyst ratings

    $FNA
    SEC Filings

    See more
    • SEC Form S-8 POS filed by Paragon 28 Inc.

      S-8 POS - Paragon 28, Inc. (0001531978) (Filer)

      4/21/25 4:24:46 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 POS filed by Paragon 28 Inc.

      S-8 POS - Paragon 28, Inc. (0001531978) (Filer)

      4/21/25 4:23:46 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 POS filed by Paragon 28 Inc.

      S-8 POS - Paragon 28, Inc. (0001531978) (Filer)

      4/21/25 4:22:43 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care

    $FNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Paragon 28 Inc.

      SC 13G - Paragon 28, Inc. (0001531978) (Subject)

      8/9/24 9:02:32 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Paragon 28 Inc. (Amendment)

      SC 13G/A - Paragon 28, Inc. (0001531978) (Subject)

      2/14/24 3:29:50 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Paragon 28 Inc. (Amendment)

      SC 13G/A - Paragon 28, Inc. (0001531978) (Subject)

      2/13/24 4:23:50 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care

    $FNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Paragon 28 to Showcase Recent Product Launches at The American College of Foot and Ankle Surgeons Annual Conference

      Paragon 28, Inc. (NYSE:FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, is pleased to announce its participation in the American College of Foot and Ankle Surgeons (ACFAS) Annual Scientific Conference. From March 27-29, Paragon 28 will feature a suite of recently launched products designed to improve foot and ankle patient outcomes and surgeon experience. "We are thrilled to engage with foot and ankle specialists at ACFAS and showcase our latest innovations after an incredibly strong product launch cadence in 2024," said Albert DaCosta, CEO of Paragon 28. "Our progress and innovation in the space is a testament to our mission to continuous

      3/24/25 4:05:00 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care
    • Paragon 28 Announces Expiration of HSR Act Waiting Period for Pending Acquisition by Zimmer Biomet Under HSR Act

      Paragon 28, Inc. (NYSE:FNA) ("Paragon 28" or "Company"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act") in connection with the previously announced acquisition of Paragon 28 by Zimmer Biomet Holdings, Inc. (NYSE:ZBH) ("Zimmer Biomet"). The expiration of the waiting period under the HSR Act represents a significant milestone in the regulatory approval process, satisfying one of the conditions required to complete the proposed merger with Zimmer Biomet. With the HSR Act waiting period expired, the transaction now re

      3/11/25 4:01:00 PM ET
      $FNA
      $ZBH
      Medical/Dental Instruments
      Health Care
      Industrial Specialties
    • Paragon 28 to Feature Several Recent Product Launches at The American Academy of Orthopaedic Surgeons Annual Conference

      Paragon 28, Inc. (NYSE:FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, is pleased to announce its participation in the American Academy of Orthopaedic Surgeons ("AAOS"). From March 10th – 14th, Paragon 28 will feature a suite of recently launched products intended to enhance patient outcomes and the surgeon experience, including: SMART 28℠ Case Management Portal featuring SMART Bun-Yo-Matic℠ Digital case management platform designed to streamline surgical planning and execution, integrating AI, data analytics, and 3D modeling​. Provides an intuitive interface for case scheduling, direct communication with engineers, and conversion o

      3/7/25 4:32:00 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care

    $FNA
    Leadership Updates

    Live Leadership Updates

    See more
    • Paragon 28 Appoints Dave Demski to Board of Directors

      Paragon 28, Inc. (NYSE:FNA), (the "Company") a leader in foot and ankle surgical solutions, today announced the appointment of Dave Demski to serve as an independent director of the Company, effective immediately. Mr. Demski brings a wealth of global orthopedic expertise, with over two decades of executive leadership experience. With the addition of Mr. Demski, the Company increased the size of its Board of Directors from eight members to nine members and has further strengthened its strategic oversight and governance capabilities. Mr. Demski most recently served as the President and CEO of Globus Medical from August 2017 to April 2022, guiding the organization through a period of signifi

      12/11/24 9:00:00 AM ET
      $ATEC
      $FNA
      Medical/Dental Instruments
      Health Care
    • Appointment of Stephen M. Deitsch as new Chief Financial Officer

      OXFORD, United Kingdom, April 04, 2024 (GLOBE NEWSWIRE) -- OrganOx, a medical device company which is changing the paradigm in liver transplantation in the US and Europe with its groundbreaking normothermic machine perfusion technology, today announces that Stephen (Steve) M. Deitsch will be joining OrganOx as Chief Financial Officer ("CFO") on April 8, 2024. Steve joins OrganOx from Paragon 28 (NYSE:FNA), a leading medical device company exclusively focused on the foot and ankle orthopaedic market, where he has held the role of CFO since September 2020. Steve's leadership was instrumental in Paragon 28's successful IPO on the NYSE in the fall of 2021. Prior to Paragon 28, Steve held CFO r

      4/4/24 11:43:23 AM ET
      $FNA
      Medical/Dental Instruments
      Health Care
    • Paragon 28 Announces Appointment of Meghan Scanlon to Board of Directors

      Paragon 28, Inc. (NYSE:FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today the appointment of Meghan Scanlon to its Board of Directors. Ms. Scanlon has joined the Board's Compensation and Quality, Technology and Regulatory Committees. Ms. Scanlon has more than 20 years of senior leadership experience with global medical device companies. She currently serves as senior vice president and president, Urology and Pelvic Health, for Boston Scientific Corporation and is a member of the Boston Scientific Executive Committee. Ms. Scanlon also is a member of the Boston Scientific Global Council for Inclusion, serving as the executive sp

      3/28/22 4:02:00 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care

    $FNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Dacosta Albert returned 11,753,724 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Paragon 28, Inc. (0001531978) (Issuer)

      4/21/25 5:00:07 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care
    • Director Wright Kristina returned 32,118 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Paragon 28, Inc. (0001531978) (Issuer)

      4/21/25 5:00:10 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care
    • Chief Commercial Officer Jarboe Matthew returned 575,320 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Paragon 28, Inc. (0001531978) (Issuer)

      4/21/25 5:00:14 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care

    $FNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Paragon 28 downgraded by Needham

      Needham downgraded Paragon 28 from Buy to Hold

      1/29/25 2:02:26 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care
    • Paragon 28 downgraded by William Blair

      William Blair downgraded Paragon 28 from Outperform to Mkt Perform

      1/29/25 7:36:30 AM ET
      $FNA
      Medical/Dental Instruments
      Health Care
    • William Blair initiated coverage on Paragon 28

      William Blair initiated coverage of Paragon 28 with a rating of Outperform

      9/29/23 7:20:32 AM ET
      $FNA
      Medical/Dental Instruments
      Health Care

    $FNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Dacosta Albert bought $255,226 worth of shares (28,000 units at $9.12) (SEC Form 4)

      4 - Paragon 28, Inc. (0001531978) (Issuer)

      3/18/24 5:34:02 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care
    • Dacosta Albert bought $259,555 worth of shares (30,500 units at $8.51) (SEC Form 4)

      4 - Paragon 28, Inc. (0001531978) (Issuer)

      11/13/23 8:00:07 AM ET
      $FNA
      Medical/Dental Instruments
      Health Care

    $FNA
    Financials

    Live finance-specific insights

    See more
    • Zimmer Biomet Announces Fourth Quarter and Full-Year 2024 Financial Results

      Fourth quarter net sales of $2.023 billion increased 4.3% and 4.9% on a constant currency1 basisFourth quarter diluted earnings per share were $1.20; adjusted1 diluted earnings per share were $2.31Full-year net sales of $7.679 billion increased 3.8% and 4.8% on a constant currency1 basisFull-year diluted earnings per share were $4.43; adjusted1 diluted earnings per share were $8.00Company provides full-year 2025 financial guidanceWARSAW, Ind., Feb. 6, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter and year ended December 31, 2024.  The Company reported fourth quarter net sales of $2.023 billion, an increase of 4.3% over

      2/6/25 6:30:00 AM ET
      $FNA
      $ZBH
      Medical/Dental Instruments
      Health Care
      Industrial Specialties
    • Paragon 28 Reports Third Quarter 2024 Financial Results and Raises 2024 Net Revenue Guidance

      Paragon 28, Inc. (NYSE:FNA) ("Paragon 28" or "Company"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended September 30, 2024 and raised its 2024 net revenue guidance. Recent Business Updates Recorded global net revenue of $62.3 million in the third quarter, representing 18.1% and 17.6% reported and constant currency growth compared to the prior year period, respectively Raised net revenue guidance to $252 million to $256 million for full year 2024 net revenue, representing 16.5% to 18.3% reported growth compared to 2023 Drove a 969 basis point improvement in operating expense as a

      11/12/24 4:05:00 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care
    • Paragon 28 To Report Third Quarter 2024 Financial Results on November 12, 2024

      Paragon 28, Inc. (NYSE:FNA) ("PARAGON"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the third quarter 2024 after market close on Tuesday, November 12, 2024. The Company's management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time / 2:30 p.m. Mountain Time. Investors interested in listening to the conference call may do so by dialing (833-470-1428) for domestic callers or (404-975-4839) for international callers, using conference ID: 725499. Live audio of the webcast will be available on the "Investors" section of the Company's website at: ir.paragon28.com. The

      10/17/24 4:05:00 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care